Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Shareholder Meeting (November 2023)
46 slides from Prescient Therapeutics's shareholder meeting presentation, Nov 16, 2023
Slide 1: Investor presentation 2023 AGM Briefing
For personal use only Near term opportunities. Near term opportunities. Long term value. Long term value. Investor 2023 AGM Briefing presentation ASX: ASX: PTX PTX
Slide 2: Disclaimer and Safe Harbor
DISCLAIMER AND SAFE HARBOR For personal use only Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts b
Slide 3: Chair Address
For personal use only CHAIR ADDRESS
Slide 4: Biotech market observations
Biotech market observations For personal use only • Are we at the bottom? • How is this affecting Prescient’s activities? – Clinical candidates – CAR-T related • When will we come out of this? • What should we do now? – Companies adapt and manage financials tightly – Investors 4
Slide 5: Is biotech at the bottom?
Is biotech at the bottom? For personal use only Daily % YTD % Last PreviousDaily Change Change Change LifeSci Biotech Clinical Trials ETF (BBC) $17.40 $17.36 $0.04 0.23% -30.37% LifeSci Biotech Products ETF $47.34 $46.96 $0.38 0.81% -3.94% (BBP) AlphaCentric LifeSci Healthcare Fund Class I $11.20 $1
Slide 6: Have we improved since the second quarter?
Have we improved since the second quarter? Second quarter summary – Locust Walk For personal use only • Public markets showed some signs of stabilization but IPO, private financing and strategic dealmaking still remain below historical levels with no evidence of a near-term reversal • The broader ma
Slide 7: How is this affecting Prescient's activities?
How is this affecting Prescient’s activities? PTX- 100 For personal use only PTX 100 7
Slide 8: How is this affecting Prescient's activities? Selling into CAR-T
How is this affecting Prescient’s activities? Selling into CAR-T For personal use only 8
Slide 9: CAR-T companies in development
How is this affecting Prescient’s activities? Selling into CAR-T For personal use only CAR-T Companies in development 9
Slide 10: CAR-T landscape
How is this affecting Prescient’s activities? CAR-T For personal use only landscape • CAR-T was booming and now confronting challenges • Efficacy and durability in solid tumors unproven • T-cell exhaustion • Treatment evasion • Safety issues • Patient access and reimbursement – slow Gilead/Kite adop
Slide 11: IPOs and deals continue in CAR-T area but fewer
IPOs and deals continue in CAR-T area but fewer For personal use only 15 Nov 2023 CARGO's $281M IPO could be the last listing of 2023 after market's 'drastic turn’ 13 Nov 2023 Legend signs $100M deal with Novartis for next CAR-T bets, following up on Janssen success 11
Slide 12: What should we do now?
What should we do now? For personal use only • We have been here before - well-managed companies will do well • We do not know when the market will recover • Companies must adapt their strategies • Focus on the areas of leverage • Cut or deprioritize unproductive projects • Delay/skinny down/speed-u
Slide 13: CEO Presentation
For personal use only CEO PRESENTATION
Slide 14: Diversified portfolio of later stage and emerging assets
Diversified portfolio of later stage and emerging assets For personal use only Encouraging Ph1b data in TCL Targeted • Exceeding SoC expectations in an area of unmet need therapies Aiming for Ph2 registration trial in 2024 Cell therapy enhancement platform with demonstrated benefits ready for the cl
Slide 15: Diversified portfolio of later stage and emerging assets
Diversified portfolio of later stage and emerging assets For personal use only Encouraging Ph1b data in TCL Targeted • Exceeding SoC expectations in an area of unmet need therapies Aiming for Ph2 registration trial in 2024 Cell therapy enhancement platform with demonstrated benefits ready for the cl
Slide 16: Summary: a year of change and progress
Summary: a year of change and progress For personal use only • Phase 1b demonstrated exciting progress and data PTX-100 • Safety and patient responses beyond expect Standards of care • Planning subsequent Phase 2 in TCL 2024 • Excellent developmental progress throughout year; demonstrating cell ther
Slide 17: Market backdrop
For personal use only 17 Market backdrop
Slide 18: Persistent sector headwinds
Persistent sector headwinds For personal use only • Worst extended biotech bear market on record? • Stubbornly high inflation and high interest rates combine to devalue the biotech sector • Impacts long-dated assets • Higher returns on low-risk asset classes drains funds from biotech sector • Recess
Slide 19: Biotech valuations impacted globally
Biotech valuations impacted globally For personal use only Enterprise valuations* (a proxy for technology value) remain at low levels for the global biotechnology sector EVs are: Down 71% since peak Down 15% last 12 months >200 companies trading below cash Even though these cash levels have fallen i
Slide 20: PTX-100 First in class RAS pathway inhibitor
For personal use only PTX-100 FIRST IN CLASS RAS PATHWAY INHIBITOR 20
Slide 21: T-cell lymphomas (TCL)
T-cell lymphomas (TCL) For personal use only • TCL occurs when T-cells undergo changes • TCL represents an area of high unmet need and become cancerous • Poor patient outcomes – even responders often relapse • TCL is 10-15% of all non-Hodgkin lymphomas • New entrants, but outcomes are still poor, •
Slide 22: Advantages of Orphan Drugs
Advantages of Orphan Drugs For personal use only Orphan 11.6% CAGR 7 7 years of guaranteed market exclusivity in US Non-orphan 7% CAGR Consistently higher sales growth Enjoy higher prices than non-orphan drugs Sales are more resilient Total orphan sales to cycles to reach $US300B by 2028 Evaluate Lt
Slide 23: PTX-100's progress: what does it mean for PTX?
PTX-100’s progress: What does it mean for PTX? For personal use only • PTX is on the verge of a major inflexion point with the start of a Phase 2 study for PTX-100 • Biggest catalyst in company’s history, and the culmination of years of work • Potential for the Phase 2 trial to be a registration stu
Slide 24: Meaningful progress of PTX-100 Ph1b trial in r/rTCL
Meaningful progress of PTX-100 Ph1b trial in r/rTCL For personal use only • Ongoing encouraging data continues to unfold from Ph1b study • Data significantly more positive than 12 months ago • This time last year there were only 2 responders (2 PRs; no CRs) and much shorter PFS • Currently n=14 r/r
Slide 25: Encouraging ongoing PTX-100 Ph1b clinical results
Encouraging ongoing PTX-100 Ph1b clinical results For personal use only Clinical responses and months on treatment Expected Trial ongoing; data cut-off as at 10 July 2023 with SoC 25
Slide 26: PTX-100 Phase 2 variables for consideration
PTX-100 Phase 2 variables for consideration For personal use only Variable Considerations for PTX • PTCL, CTCL or both? Different diseases with diversity of characteristics; needs and endpoints. Do both Disease simultaneously, or lead in with one, then add an arm? • Activity seen at all doses, but m
Slide 27: PTX-100 challenges and path forward
PTX-100 challenges and path forward For personal use only Challenges Going forward • Recruitment challenges in a rare disease, but looking to • Presentation of Ph1b data at ASH (Dec 2023) expand to multiple sites in next study • Manufacturing underway (current) • 5 day I.V. dosing schedule is demand
Slide 28: PTX-200 Novel AKT inhibition
For personal use only PTX-200 NOVEL AKT INHIBITION 28
Slide 29: PTX-200 Phase 1B trial in AML
PTX-200 Phase 1B trial in AML For personal use only Status Going forward • 27 patients treated with PTX-200 at escalating • Reviewing package – possibility of not proceeding doses in combination with 200-400 mg/m2 • Finalise current study and complete data package. cytarabine (chemo) Requires minima
Slide 30: Universal, Next Generation CAR-Therapies
For personal use only Universal, Next Generation CAR-Therapies 30
Slide 31: OmniCAR: flexible, modular CAR platform
OmniCAR: flexible, modular CAR platform For personal use only Targeting ligand Using any targeting SpyTag Covalent ligand… bond Spy Catcher Associate Professor Professor Daniel J. Powell, Jr Andrew Tsourkas Signalling domain …with any immune UNARMED ARMED CAR-T cell CAR-T cell cell 31
Slide 32: OmniCAR progress
OmniCAR progress • As previously discussed, adapted to a capital limited environment for cell therapies, shifted from expensive pre-IND For personal use only work & clinical work to strengthening pre-clinical platform development • Progress of pre-clinical platform development • Explored binder PK -
Slide 33: OmniCAR: challenges & path forward
OmniCAR: challenges & path forward For personal use only Challenges • Huge expenses for internal clinical development: not only of T-cells and GMP viral vectors, but also GMP-like binders. Portfolio re-prioritisation reflects the risk-averse environment • Some models showed less control (tonic signa
Slide 34: Cell Therapy Enhancements
For personal use only CELL THERAPY ENHANCEMENTS 34
Slide 35: CellPryme enhances cell therapies in two ways
CellPryme enhances cell therapies in two ways For personal use only MANUFACTURING ENHANCEMENT ADJUVANT THERAPY Non-disruptive additive Administered to patient during cell manufacturing alongside cell therapy 35
Slide 36: Manufacturing enhancement produces superior cells
For personal use only MANUFACTURING ENHANCEMENT PRODUCES SUPERIOR CELLS Control Conventional CAR-T Conventional CAR-T + CellPryme-M • 50% more “youthful” Tcm cells • Last longer; potent killing • Doubles helper Tcells • Doubles tumour control & survival 36
Slide 37: Adjuvant therapy breaches the cancer's castle walls
↑4x tumour For personal use only ADJUVANT THERAPY ↑9x expansion penetration BREACHES THE CANCER’S CASTLE WALLS • 9X more CAR-T cells 60 • 4x penetration the cancer’s Tumour size (mm2) protective barriers 40 • Very strong cancer killing 20 synergies with CellPryme-M! 0 7 8 9 10 11 12 13 14 15 Days Po
Slide 38: CellPryme: technical progress
CellPryme: technical progress For personal use only • Validation from 10 repeated in vitro studies and 3 repeated in vivo studies • CP-M: Improvements to exposure protocol • Stabilised CAR expression • Further increase in central memory CAR-T cells • Repeat antigen stimulation models • Prevented CAR
Slide 39: CellPryme: building awareness
CellPryme: building awareness For personal use only Progress Context & learnings • Strong promotion to potential partners and • These parties did not even think of PTX as a partner a year collaborators ago. Now PTX has dozens of new relationships and multiple ongoing conversations based on reputatio
Slide 40: CellPryme: challenges & path forward
Cellpryme: challenges & path forward For personal use only Challenges Going forward • Clarity on regulatory documentation required for both • Preparation of regulatory packages CellPryme-M and CellPryme-A (as it straddles different regulatory divisions) • Seek leverage into clinical trials with part
Slide 41: CellPryme: BD efforts
CellPryme: BD efforts For personal use only • Dozens of active business development discussions • Numbers are highly fluid • Trade off between our interest in them vs their interest in us • Most discussions are for CellPryme-M (easier to test & integrate) • As conversations proceed, some invariably
Slide 42: Summary
For personal use only Summary 42
Slide 43: Major catalysts to work towards next year
Major catalysts to work towards next year Prescient will continue to progress the development of programs across its pipeline. Some notable catalysts to For personal use only work towards include, but are not limited to: Q1 2024 Q2 2024 Q3 2024 Q4 2024 Ph 1b data FDA meeting Manuf. PTX-100 presented
Slide 44: Aspirations for each program in years if they succeed
Aspirations for each program in 5 years if they succeed For personal use only Not everything will go to plan, but any one of these successes could be transformative for PTX • PTX-100 • Approved in r/r TCLs • In additional Phase 2 trials to dominate TCL: • Combination therapies • Earlier lines of the
Slide 45: Key Messages
3 Key Messages For personal use only Encouraging Ph1b data in TCL 1 PTX-100 • Exceeding SoC expectations in an area of unmet need Aiming for Ph2 registration trial in 2024 Lower risk exposure to cell therapy 2 • Improve existing and emerging cell therapies • Agnostic on cell type and targets 3 ~$19M
Slide 46: Thank you!
For personal use only Thank you! ASX code: PTX www.ptxtherapeutics.com
Prescient Therapeutics — Shareholder Meeting (November 2023) on 6ix